La Jolla Pharmaceutical Company (LJPC)
| Market Cap | 96.35M |
| Revenue (ttm) | 52.01M |
| Net Income (ttm) | 5.24M |
| Shares Out | 25.56M |
| EPS (ttm) | 0.16 |
| PE Ratio | 23.27 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,381 |
| Open | 3.83 |
| Previous Close | 3.85 |
| Day's Range | 3.75 - 3.91 |
| 52-Week Range | 3.45 - 5.69 |
| Beta | 1.96 |
| Analysts | Sell |
| Price Target | 4.08 (+8.2%) |
| Earnings Date | May 20, 2022 |
About LJPC
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the Unit...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for LJPC stock is "Sell." The 12-month stock price forecast is 4.08, which is an increase of 8.22% from the latest price.
News
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights ...
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 a...
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life...
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that it will commence a share repurchase plan for up to $10 million of the Company's common stock. Repurch...
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -14.29% and 10.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 an...
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life...
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life...
La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 184.62% and 34.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and High...
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life...
Will La Jolla Pharmaceutical (LJPC) Report Negative Q2 Earnings? What You Should Know
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights ...
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suf...
La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 a...
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients sufferin...
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (E...
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients sufferin...
La Jolla Pharma (LJPC) Sees Hammer Chart Pattern: Time to Buy?
La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients sufferin...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and High...
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impr...
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Off...
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.
-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-thre...
La Jolla Pharmaceutical Company - to Acquire Tetraphase Pharmaceuticals, Inc.
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights
How La Jolla (LJPC) Stock Stands Out in a Strong Industry
La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Lags Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?